证券代码：600682 证券简称：南京新百 公告编号：临 2023-023 南京新街口百货商店股份有限公司 关于变更部分募集资金用途 并永久补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、本次募集资金投资项目基本情况及募集资金使用情况 根据《南京新街口百货商店股份有限公司发行股份购买资产并募集配套资 金暨关联交易报告书》，公司本次非公开发行募集资金扣除发行费用后的净额 将全部用于以下项目： | 单位：万元 | | --- | | 序号 | 项目名称 | 项目总投资 | 拟投入募集资金 | | --- | --- | --- | --- | | | | 额 | | | 1 | 养老护理人才培训基地项 | 26,368.00 | 25,649.99 | | | 目 | | | | 2 | 远程医疗分诊与服务平台 | 9,874.00 | 9,000.00 | | | 合计 | 36,242.00 | 34,649.99 | 证券代码：600682 证券简称：南京新百 公告编号：临 2023-023 截至 2 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-024 南京新街口百货商店股份有限公司 关于董事辞职及补选董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、关于董事辞职的情况 南京新街口百货商店股份有限公司(以下简称公司或本公司)董事会于近日 收到公司董事、副总裁许光兴先生递交的辞职报告，许光兴先生因个人原因，向 公司辞去公司董事及副总裁职务，辞职后许光兴先生将不再担任公司任何职务。 根据《公司法》、《上海证券交易所股票上市规则》以及《公司章程》有关规 定，许光兴先生辞职不会导致公司董事会成员人数低于法定要求，不会影响公司 及董事会的正常运作，辞职报告以送达董事会之日起生效。 许光兴先生在担任公司董事期间勤勉尽责，公司及董事会对许光兴先生在任 职期间为公司发展所做的贡献表示衷心感谢。 二、关于补选董事的情况 1 证券代码：600682 证券简称：南京新百 公告编号：临 2023-024 为保障公司董事会正常运转，公司董事会于 2023 年 8 月 7 日以通讯表决的 方式召开了第十届董事会第四 ...

证券代码：600682 证券简称：南京新百 公告编号：2023-022 南京新街口百货商店股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 至 2023 年 8 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 2023 年第二次临时股东大会 召开的日期时间：2023 年 8 月 24 日 14 点 00 分 召开地点：南京市秦淮区中山南路 1 号南京中心 23 楼多功能厅 股东大会召开日期：2023年8月24日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 ( ...

2023 年 8 月 9 日 1 南京新街口百货商店股份有限公司独立董事 关于公司第十届董事会第四次会议 相关事项的独立意见 根据《上市公司独立董事规则》、《上市公司治理准则》等法律法规及《公司 章程》的有关规定，作为南京新街口百货商店股份有限公司（以下简称公司）的 独立董事，在认真审阅相关材料的基础上，基于独立判断立场，现就 2023 年 8 月 7 日召开的公司第十届董事会第四次会议审议的相关议案发表如下独立意见： 一、关于补选第十届董事会非独立董事的议案 公司董事会提名钱静女士为公司第十届董事会非独立董事补选候选人，该候 选人的提名程序符合《公司法》和《证券法》等法律法规及《公司章程》的规定。 我们审阅了钱静女士的个人履历等相关资料，认为钱静女士符合公司董事任职资 格，具备与其行使职权相适应的任职条件，未发现有《公司法》第 146 条规定的 情形，以及被中国证监会确定为市场禁入者，或者禁入尚未解除的情况。我们同 意提名钱静女士为公司第十届董事会董事候选人，并同意将该议案提交至公司股 东大会审议。 二、关于变更部分募集资金用途并永久补充流动资金的议案 本次将部分募投项目部分募集资金用于永久补充流动资金有利 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-020 本议案尚需提交至公司股东大会审议。 南京新街口百货商店股份有限公司 第十届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：同意 10 票，反对 0 票，弃权 0 票。 南京新街口百货商店股份有限公司（以下简称公司）第十届董事会第四次 会议（以下简称会议）于 2023 年 8 月 7 日以通讯表决的方式召开。会议通知于 2023 年 8 月 4 日以电话或邮件的方式向全体董事发出，本次会议应参会董事 10 人，实际参会董事 10 人。本次会议的通知、召开以及参与表决董事人数均符合 有关法律、法规、规则及《公司章程》的规定。会议审议并通过了如下议案： 一、审议通过了《关于补选第十届董事会非独立董事的议案》 公司董事会非独立董事、副总裁许光兴先生因个人原因向董事会辞去公司 董事及副总裁职务。根据《公司法》、《上海证券交易所股票上市规则》及《公 司章程》的相关规定和董事会提名委员会的提名及资格审查，经公司第十届董 事会第四次 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-021 南京新街口百货商店股份有限公司 第九届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司(以下简称公司) 第九届监事会第十二次 会议 (以下简称会议)于 2023 年 8 月 7 日以通讯表决的方式召开。会议通知于 2023 年 8 月 4 日以电话或邮件的方式向全体监事发出，本次会议应参会监事 3 人， 实际参会监事 3 人。本次会议的通知、召开以及参与表决监事人数均符合有关 法律、法规、规则及《公司章程》的规定。会议审议通过了《关于变更部分募 集资金用途并永久补充流动资金的议案》，该议案尚需提交至公司股东大会审 议。 监事会认为：本次将部分募投项目部分募集资金用于永久补充流动资金有利 于更好地发挥募集资金使用效益，符合公司实际经营发展需要，符合全体股东 利益，不存在损害公司股东利益的情形；本次事项涉及的审议程序符合法律、 行政法规、部门规章及其他规范性文件的规定。经监事会审议，同意本次剩余 募 ...

华泰联合证券有限责任公司 关于南京新街口百货商店股份有限公司 变更部分募集资金用途并永久补充流动资金 的核查意见 华泰联合证券有限责任公司（以下简称"独立财务顾问"）作为南京新街口百 货商店股份有限公司（以下简称"南京新百"、"上市公司"或"公司"）发行股份购 买安康通控股有限公司（以下简称"安康通"）84%股权、Sanpower International Healthcare Group Co.,Ltd.（以下简称"三胞国际"）100%股权以及山东省齐鲁干细 胞工程有限公司 76%股权并募集配套资金暨关联交易的独立财务顾问，根据《上 海证券交易所股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金 管理和使用的监管要求》《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》等相关规定，对南京新百变更部分募集资金用途并永久补充流动资金事 项进行了审慎核查，具体情况如下： 一、募集资金的基本情况 1 二、募集资金的使用情况 根据《南京新街口百货商店股份有限公司发行股份购买资产并募集配套资 金暨关联交易报告书》，公司本次非公开发行募集资金扣除发行费用后的净额 将全部用于以下项目： 三、募集资金 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-015 南京新街口百货商店股份有限公司 关于召开 2022 年度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 南京新街口百货商店股份有限公司（以下简称公司）已于 2023 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）发布公司 2022 年度报告，为便于 广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况及利润分配方 案，公司计划于 2023 年 05 月 16 日下午 15:00-16:00 举行 2022 年度业绩暨现 金分红说明会，就投资者关心的问题进行交流。 证券代码：600682 证券简称：南京新百 公告编号：临 2023-015 二、 说明会召开的时间、地点 三、 参加人员 总经理：张轩先生 会议召开时间：2023 年 05 月 16 日(星期二)下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow ...

Financial Performance - Net profit attributable to shareholders decreased by 14.94% year-to-date compared to the previous year[5] - Net profit excluding non-recurring gains and losses decreased by 18.15% year-to-date[5] - Basic and diluted earnings per share both decreased by 18.75% year-to-date[5] - Net profit for Q1 2023 was RMB 226,501,212.08, down from RMB 251,537,370.90 in Q1 2022[14] - Comprehensive income for Q1 2023 totaled RMB 94,650,336.08, compared to RMB 194,242,281.97 in Q1 2022[14] - The basic earnings per share for Q1 2023 was ¥0.13, down 18.75% from ¥0.16 in Q1 2022[23] - The weighted average return on equity for Q1 2023 was 1.06%, a decrease of 0.17 percentage points compared to 1.23% in the same period last year[23] - The net profit attributable to shareholders of the listed company was ¥180,148,875.72, a decrease of 14.94% from ¥210,028,853.25 in the previous year[51] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥165,411,902.37, down 18.15% from ¥202,084,526.24 in the same period last year[51] Revenue and Costs - Total operating revenue for Q1 2023 was RMB 1,595,560,833.41, an increase from RMB 1,524,888,877.17 in Q1 2022[12] - The company's operating revenue for Q1 2023 was ¥1,595,560,833.41, representing a year-over-year increase of 4.63% compared to ¥1,398,864,221.81 in the same period last year[51] - Total operating costs for the period were approximately $1.33 billion, an increase from $1.23 billion in the previous period, representing an increase of about 8.3%[62] - Operating profit for the period was approximately $280.45 million, down from $306.09 million in the previous period, reflecting a decrease of about 8.4%[62] - Total profit for the period was approximately $282.94 million, compared to $305.75 million in the previous period, indicating a decline of about 7.4%[62] Cash Flow and Investments - The net cash flow from operating activities for Q1 2023 was ¥225,294,070.15, a decrease of 36.94% compared to ¥357,276,453.57 in Q1 2022[16] - Cash inflow from investment activities in Q1 2023 was ¥389,749,975.92, significantly higher than ¥84,816,766.54 in Q1 2022[17] - The net cash flow from investment activities for Q1 2023 was -¥191,781,349.33, an improvement from -¥295,796,709.76 in Q1 2022[17] - Cash inflow from financing activities in Q1 2023 was ¥137,210,000.00, compared to ¥203,214,000.00 in Q1 2022[17] - The net cash flow from financing activities for Q1 2023 was -¥38,979,528.13, an improvement from -¥130,828,417.63 in Q1 2022[17] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥25,420,629,239.31, reflecting a 0.81% increase from ¥25,215,359,602.91 at the end of the previous year[23] - The company's total current assets increased to ¥8,546,905,904.46 from ¥8,163,995,535.77 year-over-year[59] - The company's total liabilities increased to ¥6,062,515,585.59 from ¥5,944,696,538.91 year-over-year[60] - The company's inventory as of March 31, 2023, was ¥378,624,983.79, up from ¥287,490,302.87 in the previous year[59] - The company reported a decrease in fixed assets to ¥2,955,435,545.40 from ¥2,999,939,557.56 year-over-year[60] Expenses - Financial expenses increased by 229.78% year-to-date, primarily due to increased deposit interest[5] - Research and development expenses were approximately $57.59 million, slightly down from $59.71 million in the previous period, a decrease of about 3.6%[62] - Sales expenses decreased to approximately $129.23 million from $155.15 million, a reduction of about 16.7%[62] - Management expenses increased to approximately $296.95 million from $243.21 million, an increase of about 22.1%[62] - Financial expenses showed a significant improvement, with a net income of approximately -$11.53 million compared to a net expense of $8.88 million in the previous period[62] - Other income for the period was approximately $1.30 million, down from $2.40 million in the previous period, a decrease of about 45.8%[62] Other Information - Other comprehensive income decreased by 42.57% at the end of the reporting period, mainly due to foreign currency translation differences[5] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[57] - The company reported investment income of approximately $5.47 million, a significant increase from $440,409.36 in the previous period[62] - The company did not report any net profit from the merged entity prior to the merger, indicating no impact on overall profitability from this activity[64]

Financial Performance - As of December 31, 2022, the total share capital of the company is 1,346,132,221 shares, with a proposed cash dividend of RMB 0.2 per 10 shares, totaling RMB 26,782,644.42 (including tax) to be distributed to shareholders[4]. - In 2022, the company achieved total operating revenue of RMB 1,524,888,877.17 in Q1, RMB 1,490,086,053.27 in Q2, RMB 1,648,365,517.36 in Q3, and RMB 1,767,336,404.13 in Q4, showing a consistent revenue growth throughout the year[27]. - The net profit attributable to shareholders for Q1 was RMB 211,801,270.50, Q2 was RMB 184,350,642.06, Q3 was RMB 217,845,594.15, and Q4 was RMB 109,502,430.24, indicating fluctuations in profitability across the quarters[27]. - The company achieved operating revenue of CNY 6,430,676,851.93 in 2022, a year-on-year increase of 0.71%[47]. - Net profit attributable to shareholders was CNY 723,499,936.95, representing a decrease of 31.41% compared to the previous year[47]. - The net cash flow from operating activities decreased by 23.85% to CNY 1,536,377,650.20[47]. - The company's total assets at the end of 2022 were CNY 25,215,359,602.91, down 5.41% from the previous year[47]. - Basic earnings per share decreased by 30.77% to CNY 0.54[49]. Business Development and Expansion - The company successfully introduced 75 new brands, including 10 first stores in Jiangsu and 3 first stores in Nanjing, enhancing its retail offerings[34]. - The company celebrated its 70th anniversary with a record total sales of RMB 1.05 billion on the anniversary day, marking a significant milestone in sales performance[34]. - The company upgraded the facade of its Nanjing flagship store, featuring Asia's largest 3D naked-eye screen, which became a landmark attraction during the New Year's Eve celebration[34]. - The company has focused on enhancing brand influence through participation in public welfare activities and optimizing business processes[56]. - The company plans to continue diversifying its business and improving management efficiency through information technology[56]. - The company achieved a year-on-year increase in the number of successful bids and project scale in the domestic Ankang Tong business, expanding into 5 new prefecture-level cities and over 30 county-level markets[68]. Cash Flow and Dividend Policy - The net cash flow from operating activities for Q1 was RMB 357,276,453.57, Q2 was RMB 322,499,816.57, Q3 was RMB 273,917,877.88, and Q4 was RMB 582,683,502.18, reflecting strong cash generation capabilities[27]. - The company plans to submit the proposed dividend distribution plan for shareholder approval, indicating a commitment to returning value to shareholders[4]. Healthcare Services and Innovations - The new health hospital recorded over 230,000 outpatient visits for the year, with a daily outpatient volume of 1,300 and a daily inpatient count exceeding 1,100[70]. - The company’s healthcare services saw a significant increase in surgical procedures, with nearly 15,000 surgeries performed, including 5,347 level-four surgeries[70]. - The company successfully launched the HeKang elderly assistance mini-program and established the Chinese medicine service brand RunHeTang, enhancing its service offerings[74]. - The company is focusing on enhancing nursing quality through a comprehensive quality management system, utilizing PDCA management methods[100]. - The hospital is committed to improving service quality and patient satisfaction through various initiatives, including the implementation of standardized service protocols[120]. Market Trends and Projections - The Chinese pharmaceutical market is projected to grow from RMB 186.8 billion in 2022 to RMB 228.73 billion by 2025, with a compound annual growth rate of 9.6%[110]. - The global oncology drug market is projected to reach nearly $270 billion by 2025, with a compound annual growth rate (CAGR) of 10.4% from 2022 to 2025[137]. - The U.S. oncology drug market was approximately $97.8 billion in 2022, with a projected growth to $141.5 billion by 2025, reflecting a CAGR of 15%[165]. - In China, the oncology drug market grew by 20% from 2020 to 2022, driven by increased insurance coverage and economic capacity[165]. Social Responsibility and Community Engagement - The company is actively involved in public welfare activities, having assisted over 200 children with blood diseases through its "Fire Seed Project" since 2013[91]. - The company has received multiple honors, including being recognized as a civilized unit in Jiangsu Province and an advanced unit for fire safety management in Nanjing[58]. Strategic Partnerships and Collaborations - The company completed a strategic partnership with Baidu and Gaode Map to leverage community station advantages for diversified online and offline services[73]. - The company’s CDMO business in the U.S. achieved a breakthrough with successful technology transfer and product trial delivery under a strategic partnership with Shoreline[69]. - Natali (China) has established a strong technical cooperation with the China-Israel Innovation Park, enhancing its product development capabilities[197]. Technology and Innovation - The company has established a digital hospital initiative aimed at achieving smart management and aligning with relevant standards for smart healthcare[128]. - The company is enhancing its information technology infrastructure to improve operational efficiency and service safety[111]. - The company has upgraded its cell factory to enhance product stability and safety, supporting critical clinical research registration[179].